Abstract
Twenty-seven patients (14 - female, 13 - male; 3 - having achieved puberty) with growth hormone receptor deficiency (Laron syndrome) received treatment with recombinant insulin-like growth factor 1 (IGF-1) at a dose of 40-120 mcg per 1 kg body weight 2 times a day for 12 months. SDS for growth at the beginning of treatment ranged from -9.1 to -3.2 (age 3.7-22.9 years). Before treatment, most patients had an increased basal concentration in the serum of growth hormone (2.4–208 mU/L) and a low serum concentration of IGF-1 (<20–69 μg/L), IGF-2 (69–295 μg/L) and IRF-binding protein-3 (0.16-1.59 mg/l). In all but the two oldest patients, the growth rate increased by more than 2 cm / year compared with those before treatment. Asymptomatic hypoglycemia (blood glucose level <3.0 mmol / L) was recorded in 10 patients in 0.7% of measurements. In 4 patients symptomatic hypoglycemia was noted. Most patients after injections showed a transient decrease in serum potassium levels.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.